CONTACT US: 1.800.301.5033


COVID-19 & The Decentralized Trial Rush: Front-Line Insights

Be wary of too-good-to-be-true solutions. That’s Clinical Ink CEO Ed Seguine’s message in this assembly of thought leaders’ expert opinions on the new, necessity-born enthusiasm for decentralized trials. What can you do? Consider direct data capture solutions (DDC) and BYOD ePRO for new studies.

This article was written by Ed Miseta, chief editor, to appear online in Clinical Leader (May 19, 2020).